ARCH Venture Partners IX Overage, L.P.
SEC CIK 1723172 · EDGAR
BoughtSold
Most active insiders at LYEL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ARCH Venture Partners IX Overage, L.P. | 10% | $12.50M | — |
| 2 | BERNS PAUL L | 10% | $12.50M | — |
| 3 | Seely Lynn | Pres, CEO, Dir | — | $353.1K |
| 4 | Bulis Veronica Sanchez | VP, Corp. Ctrl | — | $96.9K |
| 5 | Lee Gary K. | CSO | — | $71.7K |
| 6 | Hill Stephen J. | COO | — | $51.3K |
| 7 | Shook David | Chief Medical Off | — | $31.3K |
| 8 | Innovative Cellular Therapeutics Holdings Ltd | 10% | — | $274.30 |
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-03-09 | 2026-03-06 | LYEL | Lyell Immunopharma, Inc. | ARCH Venture Partners IX Overage, L.P. | 10% | P - Purchase | $25.61 | +488.1K | 1.43M | +52% | +$12.50M |
| M | 2022-06-10 | 2022-06-08 | VIR | Vir Biotechnology, Inc. | ARCH Venture Partners IX Overage, L.P. | 10% | J - Other | $0.00 | +14.6K | 15.8K | +1,158% | $0 |
| MI | 2022-06-10 | 2022-06-08 | VIR | Vir Biotechnology, Inc. | ARCH Venture Partners IX Overage, L.P. | 10% | J - Other | $0.00 | -497.0K | 7.80M | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations